Dr. Jacqueline Lui, Managing Director of Eagle IP Ltd., gave a talk on “Insights into the Patent Protection Situation in China” at Chicago branch office of Edwards Wildman Palmer.
我们的过去活动
Recommended Insights
Chinese Courts Cares More About Patent Quality Now (A Doctrine of Equivalents Story)
2022年12月13日There is no doubt that the drafting quality of a patent can be crucial in determining the success (or failure!) of the patent during litigation. However, due to various reasons, patents often fail to use the right drafting strategies that best protect the invention. Too often, inexperienced or unsophisticated patent drafters merely listen to an […]
阅读更多 >
China Releases Draft Implementation Guidelines for the Drug Administration Law
2022年6月2日The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
阅读更多 >
New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference
2024年3月21日Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
阅读更多 >
Is it Sufficient to Claim an Antibody only by Describing its Antigen?
2018年11月12日Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]
阅读更多 >